Debu Tripathy, MD | Authors




Dr. Debu Tripathy on Ribociclib Plus Hormone Therapy for Breast Cancer Patients

June 10, 2019

Cancer Network spoke with Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, on how ribociclib plus hormone therapy extends survival for patients with premenopausal advanced HR-positive breast cancer.

PARP Inhibitors: the Story is Still Unfolding

October 12, 2011

The opening chapters in the investigation of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as cancer therapeutics have been interpreted by some as a quantum leap forward in targeted and personalized medicine and by others as another example of disappointment following a flurry of promising preclinical and early clinical trials based on elegant biology.

FDA and Avastin: Crossroads in an Era of Targeted Therapies

October 25, 2010

In early 2008, based on the results of its E2100 trial, which showed significant improvements in progression-free survival when combined with paclitaxel, Avastin (bevacizumab) gained an FDA accelerated approval. Median progression-free survival in the Avastin arm was 11.3 months compared with 5.8 months for paclitaxel alone (although overall survival in the two arms was similar). However, final approval would be dependent on subsequent trials showing similar degrees of benefit. When two additional trials were submitted for review, both showed significant improvements in progression-free survival, but again with no difference in overall survival. Subsequently, on July 20th of this year, the Oncologic Drugs Advisory Committee (ODAC) voted 12 to 1 not to recommend permanent approval of Avastin as first-line therapy in advanced breast cancer.

Is ‘Maintenance Therapy’ in Metastatic Breast Cancer a Misnomer?

February 27, 2010

Ron Piana, Executive Editor for Special Projects with the journal ONCOLOGY, spoke with nationally regarded breast cancer specialist, Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference.

Praise for global study, but concern for subset

April 22, 2009

We have known for some time that endocrine-responsive patients should probably receive an AI, but studies presented at SABCS provided some answers to our questions: Should we start with tamoxifen and then switch to an AI or is the best approach to initiate treatment with an AI from the start?

New Serum Markers: More Data Needed

June 01, 2008

This practical review on the use of serum markers and circulating tumor cells (CTCs) focuses on the role of these assays in the management of patients with breast cancer and contains important information and perspectives for the practicing oncologist. The varying roles of these markers in early-stage and advanced disease are presented, and the implications in management are quite different in each setting.

Interdisciplinary Breast Cancer Care: Declaring and Improving the Standard

September 01, 2004

Multidisciplinary approachesto many human diseases areemerging as effective, patient-centered strategies in diverse areassuch as cancer, neurology, andcardiovascular disease. However, theyrequire significant organizational andfinancial resources. Dr. Rabinowitz articulatesthe key benefits of multidisciplinarycare for breast cancer, includingteam planning and coordination of care.There is not much objective informationto definitively prove that “centerbased”care leads to superior outcomesin terms of recurrence or survival. Thedata cited in this review include improvementsin measures of patient comfortand satisfaction with care, whichare important from an emotional standpointand even make business sense.This alone should motivate cancer careproviders to organize breast centers thatare designed appropriately given thesize of the population served and theresources available.